296 related articles for article (PubMed ID: 25446255)
1. VIP induces NF-κB1-nuclear localisation through different signalling pathways in human tumour and non-tumour prostate cells.
Fernández-Martínez AB; Carmena MJ; Bajo AM; Vacas E; Sánchez-Chapado M; Prieto JC
Cell Signal; 2015 Feb; 27(2):236-44. PubMed ID: 25446255
[TBL] [Abstract][Full Text] [Related]
2. Vasoactive intestinal peptide induces cyclooxygenase-2 expression through nuclear factor-kappaB in human prostate cell lines Differential time-dependent responses in cancer progression.
Fernández-Martínez AB; Collado B; Bajo AM; Sánchez-Chapado M; Prieto JC; Carmena MJ
Mol Cell Endocrinol; 2007 May; 270(1-2):8-16. PubMed ID: 17434257
[TBL] [Abstract][Full Text] [Related]
3. Vasoactive intestinal peptide transactivates the androgen receptor through a protein kinase A-dependent extracellular signal-regulated kinase pathway in prostate cancer LNCaP cells.
Xie Y; Wolff DW; Lin MF; Tu Y
Mol Pharmacol; 2007 Jul; 72(1):73-85. PubMed ID: 17430995
[TBL] [Abstract][Full Text] [Related]
4. Vasoactive intestinal peptide increases vascular endothelial growth factor expression and neuroendocrine differentiation in human prostate cancer LNCaP cells.
Collado B; Gutiérrez-Cañas I; Rodríguez-Henche N; Prieto JC; Carmena MJ
Regul Pept; 2004 Jun; 119(1-2):69-75. PubMed ID: 15093699
[TBL] [Abstract][Full Text] [Related]
5. Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide inhibit nuclear factor-kappa B-dependent gene activation at multiple levels in the human monocytic cell line THP-1.
Delgado M; Ganea D
J Biol Chem; 2001 Jan; 276(1):369-80. PubMed ID: 11029467
[TBL] [Abstract][Full Text] [Related]
6. Prostaglandin E2 induces vascular endothelial growth factor secretion in prostate cancer cells through EP2 receptor-mediated cAMP pathway.
Wang X; Klein RD
Mol Carcinog; 2007 Nov; 46(11):912-23. PubMed ID: 17427962
[TBL] [Abstract][Full Text] [Related]
7. Vasoactive intestinal peptide increases VEGF expression to promote proliferation of brain vascular endothelial cells via the cAMP/PKA pathway after ischemic insult in vitro.
Yang J; Shi QD; Song TB; Feng GF; Zang WJ; Zong CH; Chang L
Peptides; 2013 Apr; 42():105-11. PubMed ID: 23340020
[TBL] [Abstract][Full Text] [Related]
8. Vasoactive intestinal peptide induces neuroendocrine differentiation in the LNCaP prostate cancer cell line through PKA, ERK, and PI3K.
Gutiérrez-Cañas I; Juarranz MG; Collado B; Rodríguez-Henche N; Chiloeches A; Prieto JC; Carmena MJ
Prostate; 2005 Apr; 63(1):44-55. PubMed ID: 15468165
[TBL] [Abstract][Full Text] [Related]
9. Vasoactive intestinal peptide (VIP) induces c-fos expression in LNCaP prostate cancer cells through a mechanism that involves Ca2+ signalling. Implications in angiogenesis and neuroendocrine differentiation.
Collado B; Sánchez MG; Díaz-Laviada I; Prieto JC; Carmena MJ
Biochim Biophys Acta; 2005 Jun; 1744(2):224-33. PubMed ID: 15921770
[TBL] [Abstract][Full Text] [Related]
10. Forskolin increases angiogenesis through the coordinated cross-talk of PKA-dependent VEGF expression and Epac-mediated PI3K/Akt/eNOS signaling.
Namkoong S; Kim CK; Cho YL; Kim JH; Lee H; Ha KS; Choe J; Kim PH; Won MH; Kwon YG; Shim EB; Kim YM
Cell Signal; 2009 Jun; 21(6):906-15. PubMed ID: 19385062
[TBL] [Abstract][Full Text] [Related]
11. Vasoactive intestinal peptide (VIP) increases vascular endothelial growth factor (VEGF) expression and secretion in human breast cancer cells.
Valdehita A; Carmena MJ; Collado B; Prieto JC; Bajo AM
Regul Pept; 2007 Dec; 144(1-3):101-8. PubMed ID: 17683807
[TBL] [Abstract][Full Text] [Related]
12. Transactivation of HER2 by vasoactive intestinal peptide in experimental prostate cancer: Antagonistic action of an analog of growth-hormone-releasing hormone.
Sotomayor S; Carmena MJ; Schally AV; Varga JL; Sánchez-Chapado M; Prieto JC; Bajo AM
Int J Oncol; 2007 Nov; 31(5):1223-30. PubMed ID: 17912451
[TBL] [Abstract][Full Text] [Related]
13. Vasoactive intestinal peptide behaves as a pro-metastatic factor in human prostate cancer cells.
Fernández-Martínez AB; Bajo AM; Sánchez-Chapado M; Prieto JC; Carmena MJ
Prostate; 2009 May; 69(7):774-86. PubMed ID: 19189304
[TBL] [Abstract][Full Text] [Related]
14. Hypoxia regulation of expression and angiogenic effects of vasoactive intestinal peptide (VIP) and VIP receptors in LNCaP prostate cancer cells.
Collado B; Sánchez-Chapado M; Prieto JC; Carmena MJ
Mol Cell Endocrinol; 2006 Apr; 249(1-2):116-22. PubMed ID: 16563610
[TBL] [Abstract][Full Text] [Related]
15. VIP differentially activates beta2 integrins, CR1, and matrix metalloproteinase-9 in human monocytes through cAMP/PKA, EPAC, and PI-3K signaling pathways via VIP receptor type 1 and FPRL1.
El Zein N; Badran B; Sariban E
J Leukoc Biol; 2008 Apr; 83(4):972-81. PubMed ID: 18174366
[TBL] [Abstract][Full Text] [Related]
16. Multifunctional role of VIP in prostate cancer progression in a xenograft model: suppression by curcumin and COX-2 inhibitor NS-398.
Fernández-Martínez AB; Bajo AM; Valdehita A; Isabel Arenas M; Sánchez-Chapado M; Carmena MJ; Prieto JC
Peptides; 2009 Dec; 30(12):2357-64. PubMed ID: 19772879
[TBL] [Abstract][Full Text] [Related]
17. Vasoactive intestinal peptide upregulates MUC2 intestinal mucin via CREB/ATF1.
Hokari R; Lee H; Crawley SC; Yang SC; Gum JR; Miura S; Kim YS
Am J Physiol Gastrointest Liver Physiol; 2005 Nov; 289(5):G949-59. PubMed ID: 16227528
[TBL] [Abstract][Full Text] [Related]
18. EP4 receptor signalling in immature B cells involves cAMP and NF-κB dependent pathways.
Prijatelj M; Celhar T; Gobec M; Mlinaric-Rascan I
J Pharm Pharmacol; 2012 Aug; 64(8):1090-8. PubMed ID: 22775212
[TBL] [Abstract][Full Text] [Related]
19. Vasoactive intestinal peptide (VIP) inhibits human renal cell carcinoma proliferation.
Vacas E; Fernández-Martínez AB; Bajo AM; Sánchez-Chapado M; Schally AV; Prieto JC; Carmena MJ
Biochim Biophys Acta; 2012 Oct; 1823(10):1676-85. PubMed ID: 22728770
[TBL] [Abstract][Full Text] [Related]
20. Regulation of bombesin-stimulated cyclooxygenase-2 expression in prostate cancer cells.
Wen X; Chao C; Ives K; Hellmich MR
BMC Mol Biol; 2011 Jul; 12():29. PubMed ID: 21745389
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
